ALIVUS

Alivus Life Sciences Ltd., formerly Glenmark Life Sciences Ltd., is a pharmaceutical and chemical manufacturing company specializing in the development and production of select high-value, non-commoditized active pharmaceutical ingredients (APIs) focused on chronic therapeutic areas such as cardiovascular disease, central nervous system disorders, pain management, and diabetes. The company operates in two main segments: manufacturing APIs and providing contract development and manufacturing services to specialty pharmaceutical companies. With over 700 customers globally, Alivus serves markets in North America, Europe, Japan, and more than 75 countries worldwide. It is a subsidiary of Nirma Limited, a diversified conglomerate involved in consumer products, cement, chemicals, and pharmaceuticals. In early 2024, Alivus transitioned to new ownership under Nirma Limited, moving from its previous status as a captive entity under Glenmark Pharmaceuticals to an independent global company.